Karin Leandersson
YOU?
Author Swipe
View article: Spatial TCR clonality and clonal expansion in the in situ microenvironment of non-small cell lung cancer
Spatial TCR clonality and clonal expansion in the in situ microenvironment of non-small cell lung cancer Open
Background T-cell activation and clonal expansion are essential to effective immunotherapy responses in non-small cell lung cancer (NSCLC). The distribution of T-cell clones may offer insights into immunogenic mechanisms and imply potentia…
View article: Myeloperoxidase expressing tumor associated neutrophils are associated with worse prognosis in metastatic breast cancer patients
Myeloperoxidase expressing tumor associated neutrophils are associated with worse prognosis in metastatic breast cancer patients Open
Tumor associated neutrophils (TANs) exert dual and opposing functions in tumors, acting pro-tumorigenic and anti-tumorigenic, depending on tumor progression, polarization state and subtype. Consequently, the prognostic impact of TANs in br…
View article: Shedding of mitochondrial Voltage-Dependent Anion Channel-1 (VDAC1) Reflects COVID-19 Severity and Reveals Macrophage Dysfunction
Shedding of mitochondrial Voltage-Dependent Anion Channel-1 (VDAC1) Reflects COVID-19 Severity and Reveals Macrophage Dysfunction Open
COVID-19 severity correlates with lymphopenia and increased pro-inflammatory cytokines. However, the dysfunction of tissue macrophages in COVID-19 patients during the inflammatory cytokine storm has not been fully elucidated. Hospitalized …
View article: Supplementary Figure 6 from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment
Supplementary Figure 6 from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment Open
Supplementary figure 6. FH expression in glioma correlates with pro-tumorigenic markers
View article: Figure 6 from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment
Figure 6 from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment Open
FH is expressed in human glioma and correlates with disease severity. FH is produced in human lower-grade glioma (A) and GBM (B). C, FH expression correlates with decreased overall survival (C) and disease-free survival (D) of patients wit…
View article: Supplementary Figure 5 from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment
Supplementary Figure 5 from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment Open
Supplementary figure 5. FH, ICOSL and ICOS dependence on glioma patient survival. The survival data of n = 509 patients from TCGA provisional dataset brain lower-grade glioma, analyzed with cBioPortal. Statistical tests: Logrank Test.
View article: Supplementary Figure 2 from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment
Supplementary Figure 2 from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment Open
Supplementary figure 2. FH in Ntv-a mouse model (A) Mouse FH binds to mouse derived primary Tregs. Tregs were incubated for 2 h at 4oC with fluorescently labeled 25 or 100 μg/mL FH. The binding was detected using flow cytometry. (B) Wester…
View article: Supplementary Figure 3 from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment
Supplementary Figure 3 from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment Open
Supplementary figure 3. Direct effect of FH on glioma cells Proliferation of PIGPC cells treated with medium only, 25- or 100-μg/mL FH (A) and H4 mock or FH-transfected (B) was analyzed after 24, 48, 72 and 96 hours using CyQUANT assay. Da…
View article: Data from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment
Data from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment Open
The survival rate of patients with glioma has not significantly increased in recent years despite aggressive treatment and advances in immunotherapy. The limited response to treatments is partially attributed to the immunosuppressive tumor…
View article: Figure 4 from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment
Figure 4 from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment Open
FH knockdown is associated with a lower number of ICOS+ Tregs in a murine glioma model. FH expression was investigated in murine gliomas generated using the RCAS/tv-a vectors to induce expression of PDGFB (A and B) and shp53 (B). C, Schema…
View article: Supplementary Figure 4 from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment
Supplementary Figure 4 from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment Open
Supplementary figure 4. Staining control for human samples and additional information about patients (A) Histology and (B) clinical parameters of glioma patients. MGMT-methylation status; TMZ-temozolomide; Adj-adjusted. WT – wild type.
View article: Figure 1 from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment
Figure 1 from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment Open
FH binds to T cells via ICOS. A, Biotinylated FH binds to CD4+ T cells upon incubation for 2 hours with TexMACS medium alone and supplemented with 50 and 100 μg/mL FH. B, Fractionation detecting FH binding but not internalization into CD4+…
View article: Figure 3 from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment
Figure 3 from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment Open
FH enhances the immunosuppressive function of Tregs. A, FH increases the immunosuppressive effect of Tregs. Tregs were incubated in medium only or supplemented with 150 μg/mL FH. CD4+ T cells were isolated from the same donor and coculture…
View article: Figure 5 from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment
Figure 5 from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment Open
ICOS is associated with poor prognosis of patients with glioma. A, ICOS expression correlates with decreased survival of patients with glioma. Expression of ICOS correlates with neoplasm histological grade (B), cancer type (C), and EGFR mu…
View article: Figure 7 from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment
Figure 7 from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment Open
FH in glioma correlates with Treg occurrence and increased Treg viability. FH expression positively correlates with infiltration of Tregs in lower-grade glioma (A) and GBM (B). C, Western blot detecting FH in supernatants of FH-transfected…
View article: Figure 2 from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment
Figure 2 from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment Open
FH increases the viability of Tregs. FH-rendered increase in survival of CD4+ (A) but not CD8+ (B) or naïve CD4+ (C) T cells. FH increased survival of Tregs (D) and did not increase survival of Treg-depleted CD4+ T cells (E). Cells were in…
View article: Supplementary Figure 1 from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment
Supplementary Figure 1 from Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment Open
Supplementary figure 1. FH binds to T-cells via ICOS
View article: Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment
Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment Open
The survival rate of patients with glioma has not significantly increased in recent years despite aggressive treatment and advances in immunotherapy. The limited response to treatments is partially attributed to the immunosuppressive tumor…
View article: Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort
Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort Open
Background Immune checkpoint inhibitors are now a part of the treatment arsenal for triple-negative breast cancer (TNBC) but refinement of PD-L1 as a prognostic and predictive biomarker is a clinical priority. We aimed to evaluate the rele…
View article: Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort
Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort Open
Background Immune checkpoint inhibitors are now a part of the treatment arsenal for triple-negative breast cancer (TNBC) but refinement of PD-L1 as a prognostic and predictive biomarker is a clinical priority. We aimed to evaluate the rele…
View article: 62P Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: Results from a population-based cohort
62P Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: Results from a population-based cohort Open
Immune checkpoint inhibitors are now a part of the treatment arsenal for triple-negative breast cancer (TNBC) but refinement of PD-L1 as a prognostic and predictive biomarker in TNBC is a clinical priority. We aimed to evaluate the relevan…
View article: AIRE is expressed in breast cancer TANs and TAMs to regulate the extrinsic apoptotic pathway and inflammation
AIRE is expressed in breast cancer TANs and TAMs to regulate the extrinsic apoptotic pathway and inflammation Open
The autoimmune regulator (AIRE) is a transcriptional regulator expressed in the thymus and is necessary for maintaining immunological self-tolerance. Extrathymic AIRE expression is rare, and a role for AIRE in tumor-associated innate immun…
View article: TMIC-62. COMPLEMENT FACTOR H IS A NOVEL LIGAND FOR THE INDUCIBLE T CELL CO-STIMULATOR AND PROMOTES SURVIVAL OF REGULATORY T CELLS IN THE GLIOMA MICROENVIRONMENT
TMIC-62. COMPLEMENT FACTOR H IS A NOVEL LIGAND FOR THE INDUCIBLE T CELL CO-STIMULATOR AND PROMOTES SURVIVAL OF REGULATORY T CELLS IN THE GLIOMA MICROENVIRONMENT Open
The survival rates of glioma patients have not shown significant improvement in recent years despite aggressive treatment and advancements in immunotherapy. This lack of response to treatment can be attributed in part to the immunosuppress…
View article: Breast cancer associated CD169+ macrophages possess broad immunosuppressive functions but enhance antibody secretion by activated B cells
Breast cancer associated CD169+ macrophages possess broad immunosuppressive functions but enhance antibody secretion by activated B cells Open
CD169 + resident macrophages in lymph nodes of breast cancer patients are for unknown reasons associated with a beneficial prognosis. This contrasts CD169 + macrophages present in primary breast tumors (CD169 + TAMs), that correlate with a…
View article: Supplementary Data from Branching Copy-Number Evolution and Parallel Immune Profiles across the Regional Tumor Space of Resected Pancreatic Cancer
Supplementary Data from Branching Copy-Number Evolution and Parallel Immune Profiles across the Regional Tumor Space of Resected Pancreatic Cancer Open
Supplementary Data from Branching Copy-Number Evolution and Parallel Immune Profiles across the Regional Tumor Space of Resected Pancreatic Cancer
View article: Data from Branching Copy-Number Evolution and Parallel Immune Profiles across the Regional Tumor Space of Resected Pancreatic Cancer
Data from Branching Copy-Number Evolution and Parallel Immune Profiles across the Regional Tumor Space of Resected Pancreatic Cancer Open
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal disease. The only option for curative treatment is resection of the tumor followed by standard adjuvant chemotherapy. Yet, early relapse due to chemoresistance is almost inevi…